Aarti Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2025. Further, the company has informed the Exchange regarding voting results.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Drugs Limited held its 40th Annual General Meeting on September 24, 2025, via video conferencing. All 5 resolutions were passed with overwhelming majority, each receiving over 99.95% votes in favour. The resolutions covered adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025, re-appointment of Shri Harshit Manilal Savla as a director (retiring by rotation), revision in terms and conditions of Executive Directors' appointment, appointment of a Secretarial Auditor for 5 consecutive financial years, and ratification of Cost Auditor remuneration for FY 2025-26. Out of 91,270,000 total outstanding shares, 68,079,019 shares (about 74.59%) were voted. Only 99 shareholders attended the meeting through video conferencing out of 156,630 shareholders on record date. The scrutinizer was CS Ronak Kalathiya of M/s. Mehta & Mehta, Practicing Company Secretaries.
Smooth passage of all resolutions with near-unanimous support signals strong shareholder confidence in management. The revision in Executive Directors' terms is a noteworthy item that may affect future executive compensation.